Drugs / Sibofimloc
Sibofimloc
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03709628 | Mar 2018 → Nov 2019 | Crohn disease | Enterome | Completed | No outcome recorded |
| Phase 1 | NCT02998190 | Nov 2016 → Apr 2017 | — | Enterome | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT03943446 | Aug 2020 → Aug 2022 | Crohn disease | Takeda | Terminated | Missed primary Stop: Enrollment |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2021-09-16 | Enterome | Results Enterome highlights Microbiome publication describing sibofimloc’s novel mechanism of action for the treatment of Crohn’s disease enterome.com ↗
In the paper, the authors showed that blocking the adhesion of overabundant FimH-expressing bacteria to the gut wall is a promising therapeutic mechanism that effectively disarms these virulent bacteria without killing them. |
| 2017-10-27 | Enterome | Results Enterome’s EB8018, a first-in-class drug candidate targeting Crohn’s disease, successfully completes Phase I study in healthy volunteers enterome.com ↗
EB8018 was found to be well tolerated in healthy volunteers across a wide range of doses tested. |
All press releases naming this drug 5 releases
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sibofimloc | “The drug being tested in this study is called TAK-018 (Sibofimloc).” NCT03943446 ↗ |
| Known as | EB8018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03709628 ↗ |
| Known as | TAK-018 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03943446 ↗ |
| Known as | VRT-1353385 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4594305 ↗ |
| Action | Inhibit | “designed to block FimH” NCT02998190 ↗ |
| Modality | Small molecule | “EB8018 is an oral small molecule” NCT02998190 ↗ |
| Route | Oral | “Single oral dose of EB8018” NCT02998190 ↗ |